HIK — Hikma Pharmaceuticals Balance Sheet
0.000.00%
- £3.94bn
- £4.93bn
- $3.16bn
- 83
- 55
- 56
- 76
Annual balance sheet for Hikma Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 347 | 450 | 292 | 229 | 213 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 734 | 876 | 841 | 873 | 973 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,922 | 2,094 | 1,999 | 2,100 | 2,263 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,068 | 1,146 | 1,081 | 1,141 | 1,326 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 4,135 | 4,372 | 4,471 | 4,680 | 5,133 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,028 | 1,016 | 1,077 | 1,339 | 1,978 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2,000 | 1,919 | 2,336 | 2,482 | 2,823 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 2,135 | 2,453 | 2,135 | 2,198 | 2,310 |
| Total Liabilities & Shareholders' Equity | 4,135 | 4,372 | 4,471 | 4,680 | 5,133 |
| Total Common Shares Outstanding |